Citius Pharmaceuticals Q2 revenue rises on LYMPHIR launch

Citius Pharmaceuticals

15/05/2026 21:42

Overview

U.S. biopharma firm's fiscal Q2 revenue reached $1.7 mln, up from zero a year ago

Quarterly revenue fell from Q1 due to larger initial launch orders in prior quarter

Company posted net loss of $21.2 mln, or $(0.95) per share, for the quarter

Outlook

Company expects to complete LYMPHIR commercial field force buildout by mid-summer

Citius says it has sufficient inventory to meet anticipated commercial and international demand

Company expects to have sufficient funds to continue operations through November 2026

Result Drivers

LYMPHIR LAUNCH - Revenue driven by ongoing commercial launch of LYMPHIR, with $1.7 mln in Q2 sales and high gross margins

DISTRIBUTOR ORDER PATTERN - Quarter-over-quarter revenue decline reflects larger initial orders from specialty distributors at launch in Q1

ONE-TIME CHARGE - G&A expenses rose sharply due to a $19.7 mln one-time contract cancellation charge

Company press release: ID:nPn7P62Xda

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$21.20 mln
Q2 Basic EPS
-$0.95


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $6.00, about 733.3% above its May 14 closing price of $0.72

The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 0 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)